# Low Dose Epcoritamab Plus GemOx in R/R DLBCL

> **NCT07451652** · PHASE2 · RECRUITING · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed/Refractory Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Gemcitabine (1000 mg/m2)
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT07451652
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07451652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07451652, "Low Dose Epcoritamab Plus GemOx in R/R DLBCL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07451652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*